EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains

Maximillian Woodall iD, Samuel Ellis iD, Shengyuan Zhang, Japhette Kembou-Ringert, Kerry-Anne Kite, Laura Buggiotti, Amy I Jacobs, Akosua Adom Agyeman, Tereza Masonou, Machaela Palor, Timothy D McHugh, Judith Breuer und 2 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01233-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Maximillian Woodall und 13 weiteren Autor:innen. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, London, United Kingdom. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Great Ormond Street Hospital Charity (GOSH), John Black Charitable Foundation (JBCF), NIHR | NIHR Great Ormond Street Hospital Biomedical Research Centre (BRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel and repurposed antiviral drugs are available for the treatment of coronavirus disease 2019 (COVID-19). However, antiviral combinations may be more potent and lead to faster viral clearance, but the methods for screening antiviral combinations against respiratory viruses are not well established and labor-intensive. Here, we describe a time-efficient (72–96 h) and simple in vitro drug-sensitivity assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using standard 96-well plates. We employ different synergy models (zero interaction potency, highest single agent, Loewe, Bliss) to determine the efficacy of antiviral therapies and synergistic combinations against ancestral and emerging clinical SARS-CoV-2 strains. We found that monotherapy of remdesivir, nirmatrelvir, and active metabolite of molnupiravir (EIDD-1931) demonstrated baseline EC50s within clinically achievable levels of 4.34 mg/L (CI: 3.74–4.94 mg/L), 1.25 mg/L (CI: 1.10–1.45 mg/L), and 0.25 mg/L (CI: 0.20–0.30 mg/L), respectively, against the ancestral SARS-CoV-2 strain. However, their efficacy varied against newer Omicron variants BA.1.1.15 and BA.2, particularly with the protease inhibitor nirmatrelvir. We also found that remdesivir and nirmatrelvir have a consistent, strong synergistic effect (Bliss synergy score >10) at clinically relevant drug concentrations (nirmatrelvir 0.25–1 mg/L with remdesivir 1–4 mg/L) across all SARS-CoV-2 strains tested. This method offers a practical tool that streamlines the identification of effective combination therapies and the detection of antiviral resistance. Our findings support the use of antiviral drug combinations targeting multiple viral components to enhance COVID-19 treatment efficacy, particularly in the context of emerging viral strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentHumansDrug SynergismAdenosine MonophosphateAlanineHydroxylaminesCytidineProlineCOVID-19Microbial Sensitivity TestsImines

Stichwörter der Autor:innen

COVID-19OmicronSARS-CoV-2drug synergyin vitro assayinfection

Substanzen

Antiviral AgentsremdesivirAdenosine MonophosphateAlaninemolnupiravirHydroxylaminesCytidineProlineImines

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • UCL Centre for Clinical Microbiology, Royal Free Campus, London, United Kingdom.
  • Department of Pharmacy, Great Ormond Street Hospital for Children, London, United Kingdom.

ORCID-Profile: Maximillian Woodall, Samuel Ellis, Joseph F Standing, Claire M Smith

Förderung

  • Great Ormond Street Hospital Charity (GOSH)
  • John Black Charitable Foundation (JBCF)
  • NIHR | NIHR Great Ormond Street Hospital Biomedical Research Centre (BRC)
  • UKRI | Biotechnology and Biological Sciences Research Council (BBSRC)

Zitieren

APA

Woodall, M., Ellis, S., Zhang, S., Kembou-Ringert, J., Kite, K. A., Buggiotti, L., Jacobs, A. I., Agyeman, A. A., Masonou, T., Palor, M., McHugh, T. D., Breuer, J., Standing, J. F., & Smith, C. M. (2025). Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01233-24

Vancouver

Woodall M, Ellis S, Zhang S, Kembou-Ringert J, Kite KA, Buggiotti L, et al. Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01233-24

BibTeX
@article{Woodall2025,
  author = {Woodall, Maximillian and Ellis, Samuel and Zhang, Shengyuan and Kembou-Ringert, Japhette and Kite, Kerry-Anne and Buggiotti, Laura and Jacobs, Amy I and Agyeman, Akosua Adom and Masonou, Tereza and Palor, Machaela and McHugh, Timothy D and Breuer, Judith and Standing, Joseph F and Smith, Claire M},
  title = {Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01233-24}
}
Kostenlos starten →